MDLZ trades against a final fair-value range of $54.61-$86.01, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $54.6, high $86.0, with mid-point at $70.1.
Trades at a measured discount to fair value with adequate margin of safety.
Fair value
$70
Margin of safety
+12.6%
Confidence
82/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$61.29Price
Low $54.61
Mid $70.11
High $86.01
MDLZ trades against a final fair-value range of $54.61-$86.01, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Intangible brand equity (Oreo, Cadbury,
Intangible brand equity (Oreo, Cadbury, Ritz)
Unmatched global distribution scale
Unmatched global distribution scale
Cycle upside
Consumer resilience allows dominant brands to retain elevated pricing even as input costs normalize, driving outsized margin expansion.
Our financial-history view of MDLZ (MDLZ) covers revenue, gross profit, operating income, and net income across the past five fiscal years, with year-over-year growth and margin context for each line.
The revenue trajectory is reported in the financial-history section with year-over-year growth rates. Direction and acceleration are summarised inline; the full table sits within the parent financials tab.
We track operating income alongside operating margin so the reader can separate top-line growth from operating leverage. The numbers analysis subsection flags one-offs, restructuring, and stock-based-compensation effects when material.
Net income is shown together with EPS so dilution and buybacks are visible alongside profit. Where reported net income diverges materially from operating cash flow, the discrepancy is called out in the numbers-analysis subsection.
FAQ
MDLZ — frequently asked questions
Based on our latest analysis, MDLZ looks modestly undervalued. The current price is $61.3 versus a composite fair-value midpoint of $70.1 (range $54.6–$86.0), which implies roughly 14.4% upside to the midpoint.
Our composite fair-value range for MDLZ is $54.6–$86.0, with a midpoint of $70.1. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for MDLZ's archetype.
Our current rating for MDLZ is Buy with a confidence score of 82/100. MDLZ is rated Buy at $61.29 versus the reconciled fair value midpoint of $70.11, implying +14.39% upside/downside. Confidence is separately disclosed at 82/100. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for MDLZ are: Cocoa Super-Cycle Exhaustion; Private Label Defection; GLP-1 Demand Disruption. The single biggest risk is Cocoa Super-Cycle Exhaustion: Raw material costs structurally step up, entirely neutralizing pricing levers and crushing gross margins beyond the firm's hedging capacity.
Our current rating for MDLZ is Buy, issued with a confidence score of 82/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($54.6–$86.0) versus the current price of $61.3.
MDLZ is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for MDLZ.